Sera Prognostics (SERA) Competitors

Agilon Health (NYSE:AGL) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Do institutionals & insiders have more ownership in AGL or SERA?

54.6% of Sera Prognostics shares are held by institutional investors. 3.6% of Agilon Health shares are held by insiders. Comparatively, 13.5% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more risk & volatility, AGL or SERA?

Agilon Health has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Does the media prefer AGL or SERA?

In the previous week, Sera Prognostics had 2 more articles in the media than Agilon Health. MarketBeat recorded 11 mentions for Sera Prognostics and 9 mentions for Agilon Health. Agilon Health's average media sentiment score of 0.57 beat Sera Prognostics' score of 0.19 indicating that Agilon Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilon Health	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend AGL or SERA?

Agilon Health presently has a consensus price target of $3.07, indicating a potential upside of 157.02%. Given Agilon Health's stronger consensus rating and higher possible upside, research analysts clearly believe Agilon Health is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.11
Sera Prognostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has stronger earnings & valuation, AGL or SERA?

Sera Prognostics has lower revenue, but higher earnings than Agilon Health. Sera Prognostics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$6.06B	0.08	-$260.15M	-$0.77	-1.55
Sera Prognostics	$80K	1,490.79	-$32.90M	-$0.85	-3.72

Is AGL or SERA more profitable?

Agilon Health has a net margin of -5.35% compared to Sera Prognostics' net margin of -30,306.48%. Sera Prognostics' return on equity of -45.86% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-5.35%	-66.76%	-17.47%
Sera Prognostics	-30,306.48%	-45.86%	-34.31%

Summary

Agilon Health beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.